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cense. httpAbstract Aim: To assess the role of fertility preserving surgery in treatment of patients with stage
IA, G1 or G2 ovarian carcinoma without adjuvant chemotherapy.
Patients and methods: From 2006 to 2008, a prospective non-randomized study recruited 150
women, with suspicious early malignant ovarian mass.
Results: Among the 150 explored patients, only 43 (28.6%) patients underwent exploration. Only
32/150 (21.3%) patients had proven stage IA, either G1 or G2, epithelial ovarian cancer. Among the
32 patients, 22 (68.7%) patients were nullipara while 10 (32.1%) had one child. All patients had
unilateral tumors; 26 (81.25%) patients had G1 and 6 (18.75%) patients had G2 tumors; 24/32
(75.0%) tumors were serous, 6/32 (18.7%) were mucinous and 2/32 (6.2%) were endometrioid,
and none was clear cell type. The median follow up period was 58.5 months (ranged: 48–
72 months). Two patients (6.7%) were lost during follow up; data will be presented for the remain-
ing 30 patients. One patient, at 27th month of follow up, had open abdominal exploration to inves-
tigate abnormal pelvic mass on routine ultrasound follow up examination. Frozen section revealed
recurrent invasive mucinous tumor. She underwent radical surgery with pelvic and para-aortic
lymph node dissection, followed by adjuvant chemotherapy, and remained free of disease, for
the remaining 29 months of the follow up period. Neither distant metastases nor mortality were
reported among our patients.haba Sq., From Mosadaq St.,
720671; fax: +20 223680021.
du.eg (I. Fakhr).
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Approximately 25% of patients with the diagnosis of ovarian
cancer are classiﬁed as stage I, or with early epithelial ovarian
cancer (EOC) have ﬁve-year survival rates approaching 90%
(Incoherent phrase; how about this: Approximately 25% of pa-
tients with early epithelial ovarian cancer (EOC) are diagnosed
in early stage (FIGO I–II) with ﬁve-year survival rates
approaching 90%) [1]. More recently, ovarian cancer has been
classiﬁed histologically and biologically into type-I and type-II.
Type I tumors are generally low-grade carcinomas. They devel-
op in a slow, stepwise fashion from benign cystadenomas and
borderline tumors. They typically present at an early stage, con-
ﬁned to the ovary and are generally indolent and remain low
grade, although some of them can progress to high grade [2–4].
The deﬁnitive surgery for stage I ovarian carcinoma would
involve removal of the uterus and both ovaries and tubes in
addition to the rest of the staging procedure. The reason for
this approach is the fear of leaving an undiagnosed carcinoma
in the contralateral normal looking ovary when only one ovary
is macroscopically involved [5]. Cure or long term remission is
the most important goal of cancer treatment and the deﬁnite
therapies that are available are based on surgery, cytotoxic
medications and radiotherapy (I presume you are making a
general statement on ‘‘Cancer’’, not particularly ovarian, and
hence I added radiotherapy). In gynecological context, gener-
ally, these procedures result in infertility [6].
Several reports have estimated that 3–17% of all EOCs oc-
cur in women under 40 years of age [7–11]. In these patients,
the option of reproductive and endocrine function preserva-
tion becomes crucial. Moreover, with the constant shifting of
childbearing age toward higher ages, the increasing incidence
of EOC in women with active childbearing potential consti-
tutes a therapeutic dilemma [12]. Fertility-sparing surgery is
supported in FIGO stage I disease by a low incidence of occult
involvement of the contralateral ovary with a normal appear-
ance to the operating surgeon [13].Aim
The aim of this study was to assess the role of fertility preserv-
ing surgery in treatment of patients with FIGO stage IA, G1 or
G2, ovarian carcinoma without adjuvant chemotherapy.Materials and methods
From 2006 to 2008, a prospective non-randomized study re-
cruited 150 women, with suspicious early malignant ovarian
mass. Preoperative assessment included, complete blood
picture, liver and kidney function tests, CA-125, chest X-ray,
pelviabdominal ultrasound and pelviabdominal CT. Pelvic
MRI was only ordered in cases having complex ovarian cyst
with rather low suspicion index. All patients were offered
fertility counseling where available options were discussedthoroughly, and written informed consent was obtained from
them before inclusion in the study.
Surgery
All the 150 patients underwent primary open explorative surgery,
except for a small group of patients who had preoperative low
malignancy suspicion index, who had laparoscopic exploration.
Guided by the International Federation of Obstetrics and Gyne-
cology (FIGO) guidelines, on entering the abdomen, aspiration
of ascites or peritoneal lavage has been performed for peritoneal
cytological examination. All patients underwent unilateral sal-
pingo-oopherectomy and omentectomy. When the contralateral
ovary and the pelvi-abdominal peritoneum appeared to be free
of gross disease, random peritoneal biopsies were taken from
the pelvis, right and left para-colic gutters and the undersurfaces
of the right and left hemi-diaphragms. Similarly, when no gross
pelvic or para-aortic lymph node enlargement is reported, both
lymph node basins were randomly sampled. Ovarian and lymph
node specimenswere removed intact, to avoid tumor spillage, and
were sent to parafﬁn section examination.
Tumor staging was considered adequate if it fulﬁlled the
criteria previously described. The peritoneal cytology and the
pathology report conﬁrmed the stage. Only patients with stage
IA, both G1 and G2 ovarian carcinoma, according to the
FIGO staging system, were included in the study, and accord-
ingly received no further treatment. Cases with endometrioid
histopathology underwent endometrial curettage to exclude
concomitant endometrial cancer. Cases with higher stages
underwent completion to radical surgery with adjuvant chemo-
therapy when indicated, and where excluded from the study.
Follow up
Follow up consisted of general physical and gynecological
examination and serum CA-125 estimation every 3 months,
during the ﬁrst 2 years, and every 6 months thereafter. A pel-
vi-abdominal ultrasound was performed every 6 months and
pelvi-abdominal CT and/or MRI in case of any suspicious
ﬁnding.
Results
Among the 150 explored patients, only 43 (28.6%) patients
underwent laparoscopic exploration, while the remaining 107
(71.3%) underwent open surgical one. The steps of both explo-
ration techniques were identical. Only 32/150 (21.3%) patients
had proven stage IA, either G1 or G2, epithelial ovarian can-
cer. Among the 32 patients, 22 (68.7%) patients were nullipara
while 10 (32.1%) had one child. Patients having borderline tu-
mors were excluded from this study. All patients had unilateral
tumors, being either serous, mucinous or endometrioid cell
type. Twenty-six (81.25%) patients had G1 while the remain-
ing 6 (18.75%) patients had G2 tumors. Among these 32
patients, 24/32 (75.0%) tumors were serous, 6/32 (18.7%) were
Early Ovarian Cancer Fertility Preserving Surgery 221mucinous and 2/32 (6.2%) were endometrioid, and none was
clear cell type.
Follow up
The median follow up period was 58.5 months (ranged: 48–
72 months). Two patients (6.7%) were lost during follow up;
data will be presented for the remaining 30 patients. Three pa-
tients (10.0%) underwent second look operation after preg-
nancy during their cesarean section delivery; all of them were
free of any detectable disease. One (3.4%) patient, at 27th
month of follow up, had a localized abnormal pelvic mass
on routine ultrasound follow up examination. Further chest
and pelvi-abdominal CT scans revealed no further metastasis.
The patient underwent open abdominal exploration during
which frozen section examination revealed recurrent invasive
mucinous tumor. Completion to radical panhysterectomy with
pelvic and para-aortic lymph node dissection was done. This
was followed by adjuvant chemotherapy as outlined below,
and the patient remained free of disease, for the remaining
29 months of the follow up period. Neither distant metastases
nor mortality were reported among our patients.
Adjuvant chemotherapy
Adjuvant chemotherapy was only administered following
recurrence of invasive disease, restricted to only one case using
the following regimen: Paclitaxel 175 mg/m2 day 1, Carbo-
platin AUC5 day 1 to be repeated every 3 weeks for a total
of 6 cycles. Mid-treatment assessment (CA-125 and pelviab-
dominal US) was done after 3 cycles and conﬁrmed being free
of disease. The patient was then put on follow up schedule,
every 3 months, until the end of follow up period, which con-
ﬁrmed no new recurrence of disease.
Post-treatment conception
After treatment, only 18 women (60%) have attempted preg-
nancy, all without the use of fertility drugs. Fourteen women
(77.8%) had full term pregnancy (9 vaginal deliveries and 3
cesarean sections for obstetrical reasons) and 4 (22.2%) had
mid-trimestric abortion. None of our patients needed assisted
conception. Although 12 patients (40%) had no conception at-
tempts, only 6 of them (20%) were primarily nulliparous.
Discussion
In our study, only 43/150 (28.6%) patients who had low preop-
erative malignancy suspicious index underwent laparoscopic
exploration. The majority of our patients (107/150, 71.3%),
who had higher preoperative malignancy suspicion index,
underwent open surgical exploration to insure better surgical
exploration and staging. However, due to the early stage of
the disease included in this study, all our patients underwent
the previously described staging procedure; this aligns with the
other authors’ approaches in staging early ovarian cancer [5].
Survival at 5 years after fertility sparing surgery (FSS) for
early stage EOC depends on several prognostic factors, of
which histological grade is the most important, followed by
rupture of the capsule and FIGO substage [14]. According tothe 2007 guidelines of the American College of Obstetrics
and gynecology (ACOG), fertility-sparing surgery for repro-
ductive-age patients with invasive EOC is recommended for
G1 or G2, stage IA disease with non-clear-cell histology
[15,16]. In an equivalent manner, the European Society for
Medical Oncology (ESMO) referring in 2008 to fertility-spar-
ing techniques in EOC identiﬁed patients with unilateral stage
I tumor without dense adhesions showing favorable histology
(i.e., well or moderate differentiated, non-clear-cell histology)
as being the optimal candidates for this procedure [16].
All our patients with clinically apparent stage IA ovarian
cancer had well-differentiated (G1) or moderately-differenti-
ated tumors (G2), which may explain why there was only
one case of detected recurrence in our study, in line with other
studies where recurrence rates ranged from 1.4% to 3% in the
same stage and grades [5,17,18].
Patients with endometrioid ovarian cancer may have coex-
isting endometrioid carcinoma of the endometrium as well,
which is why uterine curettage should be performed in these
patients if hysterectomy is not performed [19]. In our study
we had 25% non-serous tumors; 19% mucinous and 6% endo-
metrioid cell types, with just one mucinous recurrence. This
can help answering the inevitable question, whether non-ser-
ous or non-endometrioid histologic subtypes should be pri-
marily excluded from any organ-preserving technique [20].
However, since no randomized trials exist or will ever exist
to prospectively evaluate and answer this question, our experi-
ence, like other authors, will remain quite limited to scattered,
retrospective case series, and this question will remain unan-
swered [20].
While the International Collaborative Ovarian Neoplasm
(ICON) 1 study indicated that adjuvant chemotherapy im-
proves survival and delay recurrence in patients with early-
stage invasive ovarian cancer [21,22], it is also necessary in
situations including unfavorable cell types and poor histologic
differentiation. The Adjuvant Chemotherapy in Ovarian Neo-
plasm (ACTION) trial, which included only high-risk-early
epithelial ovarian cancer patients, concluded that optimally
staged, early epithelial ovarian cancer patients do not beneﬁt
from the use of adjuvant chemotherapy [23,24]. A number of
studies have also concluded that the use of adjuvant chemo-
therapy offers no survival advantage to patients with well-dif-
ferentiated Stage IA epithelial ovarian cancers [21,23,25,26].
Thereby, none of our patients received chemotherapy follow-
ing primary fertility sparing surgery, except upon recurrence,
which was actually limited to a single case.
Successful pregnancies have been reported in patients after
treatment for early-stage invasive ovarian cancer [5,17,27–30].
However, there is a risk of relapse. When relapse occurs in the
contralateral ovary alone, salvage treatment may result in cure.
On the other hand, if disseminated recurrence with peritoneal
spread is observed, cure is uncommon [31]. One patient with
recurrent ovarian disease in our study had a salvage radical
surgery followed by adjuvant chemotherapy, without any fur-
ther disease progression.
In this study, 14 children were born out-of spontaneous
conceptions, which indicates that successful reproduction in
patients with stage IA, G1 or G2 ovarian cancer treated by
conservative surgery is not only possible, but probable
(60%). This conﬁrms other reports, which have documented
successful reproductive function following fertility-sparing sur-
gery [5,17,19,30].
222 I. Fakhr et al.The long-term survival of patients with stage IA epithelial
ovarian cancer treated with unilateral oophorectomy is excel-
lent; reported 5-year survival rates ranged from 89% to
100% [19,20]. We report a 4-year survival of 100%.
The results of this work support other authors’ opinions
[17], indicating that fertility-sparing surgery should be consid-
ered as a treatment option in women with stage IA, G1 or G2
epithelial ovarian cancer who desire further childbearing. One
of the limitations of the current study is the relatively limited
number of patients, when compared to the 244 patients of
the ICON trial, and the relatively short follow up period
(48–72 months).
Conclusion
Fertility preserving surgery in stage IA, G1 or G2 ovarian car-
cinoma can be considered a safe treatment option in patients
within the childbearing period.
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